Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
Cathomas, R Crabb, S Mark, M Winterhalder, R Rothermundt, C Elliott, Tony Von Burg, P Kenner, H Hayoz, S Vilei, S
Cathomas, R
Crabb, S
Mark, M
Winterhalder, R
Rothermundt, C
Elliott, Tony
Von Burg, P
Kenner, H
Hayoz, S
Vilei, S
Citations
Altmetric:
Abstract
We tested whether a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis, prolongs disease control in men with metastatic castration-resistant prostate cancer (mCRPC) after documented disease stabilization with docetaxel.
Description
Date
2016-07-25
Publisher
Collections
Keywords
Type
Article
Citation
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). 2016: Prostate